MAb-3F8 + Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) + 13-cis-Retinoic Acid
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Refractory Neuroblastoma
Conditions
Primary Refractory Neuroblastoma
Trial Timeline
Aug 1, 2009 → —
NCT ID
NCT00969722About MAb-3F8 + Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) + 13-cis-Retinoic Acid
MAb-3F8 + Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) + 13-cis-Retinoic Acid is a phase 2 stage product being developed by United Therapeutics for Primary Refractory Neuroblastoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00969722. Target conditions include Primary Refractory Neuroblastoma.
What happened to similar drugs?
20 of 20 similar drugs in Primary Refractory Neuroblastoma were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00969722 | Phase 2 | Terminated |
Competing Products
20 competing products in Primary Refractory Neuroblastoma